Menu

Markets

Research

News

Learn
Paper trading
AI Chat
WatchlistsPortfoliosAlerts
Sign in
Advertisement

Vicore Pharma Holding AB (publ) VCRE

Set alert

Price alert · VCRE

All alert types
9.80 USD -0.40 -3.92%

At close · Oct 30

9.61 -0.19 -1.94%

After hours · Oct 30, 4:00 PM ET

Bid
9.77 × 1
Ask
9.92 × 1
9.74 Day range 9.97
8.66 52-week range 16.25
YTD
-39.69%
1 year
-39.69%
Open
9.74
Prev close
10.20
Mkt cap
276.01M
Vol
11.89K
Avg vol
21.31K
EPS
-2.04
P/E
0.00
Div yield
0.00%
More statistics
Low
9.74
High
9.97
Forward P/E
0.00
Beta
0.12
Short ratio
0.15
Inst. own
0.00%
Dividend
0.00
Ex-div date
Earnings
Aug 21, 2026
50-d avg
12.28
200-d avg
12.28
1y target
35.42

2Y chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 21, 2026Earnings: —; estimate -0.04211; surprise —%
Signals (8)
NameDateAgo
SMA: BearishOct 30, 20261 day ago
SMA: BullishOct 29, 20262 days ago
MACD: Buy SignalOct 12, 20262 weeks ago
RSI: OversoldSep 25, 20261 month ago
RSI: OversoldSep 23, 20261 month ago
MACD: Sell SignalSep 15, 20261 month ago
MACD: Buy SignalSep 3, 20261 month ago
MACD: Sell SignalAug 27, 20262 months ago

Key statistics

Financials
Market cap
337.83M
Enterprise value
0
Trailing P/E
0.00
Forward P/E
0.00
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
EPS (TTM)
-2.00
Beta
0.12
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
-32.50%
Free cash flow
-241.98M
Total cash
0
Total debt
0
Return on equity
-47.19%
Shares outstanding
28.15M
Short % of float
0.00%
50-day average
12.28
200-day average
12.28

Analyst view

Consensus: none

Price target (mean) 35.42
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 21, 2026

Expected Aug 21, 2026. Consensus EPS estimate -0.41.

Earnings history

Financials — quick view

All financials
VCRE Revenue — quarterly 602.00K
2025-Q1 20252026-Q1 2026
VCRE Net income — quarterly -108.62M
2025-Q1 20252026-Q1 2026
VCRE EPS — quarterly -0.39
2025-Q1 20252026-Q1 2026

Earnings

VCRE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 21, 2026Sep 30, 2026-0.04211———
May 6, 2026Jun 30, 2026-0.0505-0.04103+0.01+18.75%
Feb 27, 2026Mar 31, 2026-0.04923-0.05843-0.01-18.69%
Nov 5, 2025Sep 30, 2025-0.05189-0.053480.00-3.06%
May 6, 2025Jun 30, 2025-0.04365———
Feb 27, 2025Mar 31, 2025-0.03211-0.0459-0.01-42.95%

About Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Sector
Healthcare
Industry
Biotechnology
Country
Sweden
Website
vicorepharma.com

News

All news

Your note

Sign in to keep a note on VCRE — it syncs with the Stock Master app.

Advertisement